Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor

Molecular Pharmaceutics

Volumn 5, Issue 4, 2008, Pages 474-486

  Plattt, Virginia M ^a   Szoka Jr , Francis C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Biodistribution; Cancer; Chemotherapy; Drug conjugate; EPR effect; Liposome; Polymer; Prodrug; Recombinant protein

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; BIWA 4; BUTYRIC ACID; CARBOXYLIC ACID; CELL SURFACE RECEPTOR; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DISACCHARIDE; DRUG CARRIER; GLUCURONIC ACID; GLYCOSAMINOGLYCAN; HERMES ANTIGEN; HYALURONIC ACID; HYALURONIDASE; HYDROXYL GROUP; LIGAND; LIPOSOME; MERTANSINE; N ACETYLGLUCOSAMINE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PRODRUG; RADIOISOTOPE; RE 186; RHENIUM 186; TECHNETIUM 99M; U 36; UNINDEXED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG TARGETING; EPITHELIUM CELL; HUMAN; IN VITRO STUDY; MACROMOLECULE; MOLECULAR INTERACTION; NECK TUMOR; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SYNTHESIS; TUMOR MODEL;

ANIMALS; ANTIBODIES; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MACROMOLECULAR SUBSTANCES; NANOMEDICINE;

EID: 51049098968     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800024g     Document Type: Conference Paper

References (89)

1. Weigel, P. H.; DeAngelis, P. L. Hyaluronan synthases: a decade-plus of novel glycosyltransferases. J. Biol. Chem. 2007, 282, 36777-36781.
2. Hua, Q.; Knudson, C. B.; Knudson, W. Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. J. Cell. Sci 1993, 106 (1), 365-375.
3. Stern, R.; Jedrzejas, M. J. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem. Rev. 2006, 106, 818-839.
4. Banerji, S.; Ni, J.; Wang, S. X.; Clasper, S.; Su, J.; Tammi, R.; Jones, M.; Jackson, D. G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 1999, 144, 789-801.
5. Zhou, B.; Weigel, J. A.; Fauss, L.; Weigel, P. H. Identification of the hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 2000, 275, 37733-37741.
6. Tammi, R.; Saamanen, A. M.; Maibach, H. I.; Tammi, M. Degradation of newly synthesized high molecular mass hyaluronan in the epidermal and dermal compartments of human skin in organ culture. J. Invest. Dermatol. 1991, 97, 126-130.
7. Fraser, J. R.; Laurent, T. C.; Laurent, U. B. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 1997, 242, 27-33.
8. Laurent, T. C.; Fraser, J. R. Catabolism of Hyaluronan. In Degradation of Bioactive Substances: Physiology and Pathophysiology; Henriksen, J. H., Ed.; CRC Press: Boston, 1991; pp 249-288.
9. Pilarski, L. M.; Masellis-Smith, A.; Belch, A. R.; Yang, B.; Savani, R. C.; Turley, E. A. RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy. Leuk. Lymphoma 1994, 14, 363-374.
10. Bourguignon, L. Y.; Zhu, H.; Shao, L.; Chen, Y. W. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J. Biol. Chem. 2000, 275, 1829-1838.
11. Bourguignon, L. Y.; Singleton, P. A.; Zhu, H.; Diedrich, F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J. Biol. Chem. 2003, 278, 29420-29434.
12. Bourguignon, L. Y.; Peyrollier, K.; Gilad, E.; Brightman, A. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes Actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J. Biol. Chem. 2007, 282, 1265-1280.
13. Naor, D.; Nedvetzki, S.; Golan, I.; Melnik, L.; Faitelson, Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 2002, 39, 527-579.
14. Akima, K.; Ito, H.; Iwata, Y.; Matsuo, K.; Watari, N.; Yanagi, M.; Hagi, H.; Oshima, K.; Yagita, A.; Atomi, Y.; Tatekawa, I. Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J. Drug Targeting 1996, 4, 1-8.
15. Park, J.; Stull, R. A.; Huang, Z.; Cao, L.; Dy, E. E.; Sperinde, J. J.; Yokoyama, J. S.; Platt, V. M.; Szoka, F. C., Jr. Matrix Attachment Anti-Tumor Therapy Mediated by 5-Fluorocytosine and a Recombinant Fusion Protein Containing TSG-6 Hyaluronan Binding Domain and Yeast Cytosine Deaminase. Mol. Pharmaceutics, submitted.
16. Sy, M. S.; Guo, Y. J.; Stamenkovic, I. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein. J. Exp. Med. 1992, 176, 623-627.
17. Mackay, C. R.; Terpe, H. J.; Stauder, R.; Marston, W. L.; Stark, H.; Gunthert, U. Expression and modulation of CD44 variant isoforms in humans. J. Cell Biol. 1994, 124, 71-82.
18. Tijink, B. M.; Buter, J.; de Bree, R.; Giaccone, G.; Lang, M. S.; Staab, A.; Leemans, C. R.; van Dongen, G. A. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. Cancer Res. 2006, 12, 6064-6072.
19. Sauter, A.; Kloft, C.; Gronau, S.; Bogeschdorfer, F.; Erhardt, T.; Golze, W.; Schroen, C.; Staab, A.; Riechelmann, H.; Hoermann, K. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int. J. Oncol. 2007, 30, 927-935.
20. Maeda, H.; Seymour, L. W.; Miyamoto, Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 1992, 3, 351-362.
21. Allen, T. M.; Cullis, P. R. Drug delivery systems: entering the mainstream. Science 2004, 303, 1818-1822.
22. Pouyani, T. and Prestwich, G.D. Functionaiized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconjugate Chem. 1994, 5, 339-347.
23. Prestwich, G. D.; Marecak, D. M.; Marecek, J. F.; Vercruysse, K. P.; Ziebell, M. R. Controlled chemical modification of hyaluronic acid: synthesis, applications, and biodegradation of hydrazide derivatives. J. Controlled Release 1998, 53, 93-103.
24. Vercruysse, K. P.; Prestwich, G. D. Hyaluronate derivatives in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1998, 15, 513-555.
25. Jaracz, S.; Chen, J.; Kuznetsova, L. V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043-5054.
26. Liao, Y. H.; Jones, S. A.; Forbes, B.; Martin, G. P.; Brown, M. B. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Delivery 2005, 12, 327-342.
27. Yadav, A. K.; Mishra, P.; Agrawal, G. P. An insight on hyaluronic acid in drug targeting and drug delivery. J. Drug Targeting 2008, 16, 91-107.
28. Luo, Y.; Prestwich, G. D. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjugate Chem. 1999, 10, 755-763.
29. Luo, Y.; Ziebell, M. R.; Prestwich, G. D. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000, 1, 208-218.
30. Katoh, S.; Zheng, Z.; Oritani, K.; Shimozato, T.; Kincade, P. W. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J. Exp. Med. 1995, 182, 419-429.
31. Skelton, T. P.; Zeng, C.; Nocks, A.; Stamenkovic, I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J. Cell Biol. 1998, 140, 431-446.
32. Rochman, M.; Moll, J.; Herrlich, P.; Wallach, S. B.; Nedvetzki, S.; Sionov, R. V.; Golan, I.; Ish-Shalom, D.; Naor, D. The CD44 receptor of lymphoma cells: structure-function relationships and mechanism of activation. Cell Adhes. Commun. 2000, 7, 331-347.
33. Hathcock, K. S.; Hirano, H.; Murakami, S.; Hodes, R. J. CD44 expression on activated B cells. Differential capacity for CD44-dependent binding to hyaluronic acid. J. Immunol. 1993, 151, 6712-6722.
34. Lesley, J.; English, N.; Perschl, A.; Gregoroff, J.; Hyman, R. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J. Exp. Med. 1995, 182, 431-437.
35. Thankamony, S. P.; Knudson, W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. J. Biol. Chem. 2006, 281, 34601-34609.
36. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Delivery Rev. 2002, 54, 631-651.
37. Eliaz, R. E.; Nir, S.; Szoka, F.C., Jr. Interactions of hyaluronan-targeted liposomes with cultured cells: modeling of binding and endocytosis. Methods Enzymol. 2004, 387, 16-33.
38. Eliaz, R. E.; Nir, S.; Marty, C.; Szoka, F.C., Jr. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 2004, 64, 711-718.
39. Harris, E. N.; Kyosseva, S. V.; Weigel, J. A.; Weigel, P. H. Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J. Biol. Chem. 2007, 282, 2785-2797.
40. Mammen, M.; Choi, S.; Whitesides, G. M. Polvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. Angew. Chem., Int. Ed. 1998, 37, 2754-2794.
41. Eliaz, R. E.; Szoka, F.C., Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001, 61, 2592-2601.
42. Lesley, J.; Hascall, V. C.; Tammi, M.; Hyman, R. Hyaluronan binding by cell surface CD44. J. Biol. Chem. 2000, 275, 26967-26975.
43. Banerji, S.; Wright, A. J.; Noble, M.; Mahoney, D. J.; Campbell, I. D.; Day, A. J.; Jackson, D. G. Structures of the CD44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat. Struct. Mol. Biol. 2007, 14, 234-239.
44. Song, G.; Liao, X.; Zhou, L.; Wu, L.; Feng, Y.; Han, Z. C. HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leuk. Res. 2004, 28, 1089-1096.
45. Quak, J. J.; Van Dongen, G.; Brakkee, J. G.; Hayashida, D. J.; Balm, A. J.; Snow, G. B.; Meijer, C. J. Production of a monoclonal antibody (K 931) to a squamous cell carcinoma associated antigen identified as the 17-1A antigen. Hybridoma 1990, 9, 377-387.
46. Brakenhoff, R. H.; van Gog, F. B.; Looney, J. E.; van Walsum, M.; Snow, G. B.; van Dongen, G. A. Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol. Immunother. 1995, 40, 191-200.
47. Heider, K. H.; Sproll, M.; Susani, S.; Patzelt, E.; Beaumier, P.; Ostermann, E.; Ahorn, H.; Adolf, G. R. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol. Immunother. 1996, 43, 245-253.
48. Stroomer, J. W.; Roos, J. C.; Sproll, M.; Quak, J. J.; Heider, K. H.; Wilhelm, B. J.; Castelijns, J. A.; Meyer, R.; Kwakkelstein, M. O.; Snow, G. B.; Adolf, G. R.; van Dongen, G. A. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 2000, 6, 3046-3055.
49. Colnot, D. R.; Wilhelm, A. J.; Cloos, J.; Roos, J. C.; de Bree, R.; Quak, J. J.; Snow, G. B.; van Dongen, G. A. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy. J. Nucl. Med. 2001, 42, 1364-1367.
50. Verel, I.; Heider, K. H.; Siegmund, M.; Ostermann, E.; Patzelt, E.; Sproll, M.; Snow, G. B.; Adolf, G. R.; van Dongen, G. A. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int. J. Cancer 2002, 99, 396-402.
51. Colnot, D. R.; Ossenkoppele, G. J.; Roos, J. C.; Quak, J. J.; de Bree, R.; Borjesson, P. K.; Huijgens, P. C.; Snow, G. B.; van Dongen, G. A. Reinfusion of unprocessed, granulocyte colonystimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin. Cancer Res. 2002, 8, 3401-3406.
52. Borjesson, P. K.; Postema, E. J.; Roos, J. C.; Colnot, D. R.; Marres, H. A.; van Schie, M. H.; Stehle, G.; de Bree, R.; Snow, G. B.; Oyen, W. J.; van Dongen, G. A. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2003, 9, 3961S-3972S.
53. Colnot, D. R.; Roos, J. C.; de Bree, R.; Wilhelm, A. J.; Kummer, J. A.; Hanft, G.; Heider, K. H.; Stehle, G.; Snow, G. B.; van Dongen, G. A. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 2003, 52, 576-582.
54. Koppe, M.; Schaijk, F.; Roos, J.; Leeuwen, P.; Heider, K. H.; Kuthan, H.; Bleichrodt, R. Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer. Cancer Biother. Radiopharm. 2004, 19, 720-729.
55. Rupp, U.; Schoendorf-Holland, E.; Eichbaum, M.; Schuetz, F.; Lauschner, I.; Schmidt, P.; Staab, A.; Hanft, G.; Huober, J.; Sinn, H. P.; Sohn, C.; Schneeweiss, A. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 2007, 18, 477-485.
56. Duncan, M. B.; Liu, M.; Fox, C.; Liu, J. Characterization of the N-deacetylase domain from the heparan sulfate N-deacetylase/ N-sulfotransferase 2. Biochem. Biophys. Res. Commun. 2006, 339, 1232-1237.
57. Coradini, D.; Zorzet, S.; Rossin, R.; Scarlata, I.; Pellizzaro, C.; Turrin, C.; Bello, M.; Cantoni, S.; Speranza, A.; Sava, G.; Mazzi, U.; Perbellini, A. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res. 2004, 10, 4822-4830.
58. Meo, C. D.; Panza, L.; Capitani, D.; Mannina, L.; Banzato, A.; Rondina, M.; Renier, D.; Rosato, A.; Crescenzi, V. Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. Biomacromolecules 2007, 8, 552-559.
59. Coradini, D.; Pellizzaro, C.; Miglierini, G.; Daidone, M. G.; Perbellini, A. Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line. Int. J. Cancer 1999, 81, 411-416.
60. Luo, Y.; Bernshaw, N. J.; Lu, Z. R.; Kopecek, J.; Prestwich, G. D. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm. Res. 2002, 19, 396-402.
61. Leonelli, F.; La Bella, A.; Francescangeli, A.; Joudioux, R.; Capodilupo, A.; Quagliariello, M.; Migneco, L. M.; Bettolo, R. M.; Crescenzi, V.; De Luca, G.; Renier, D. A New and Simply Available Class of Hydrosoluble Bioconjugates by Coupling Paclitaxel to Hyaluronic Acid through a 4-Hydroxybutanoic Acid Derived Linker. Helv. Chim. Acta 2005, 88, 154-159.
62. Auzenae, E.; Ghosh, S. C.; Khodadadian, M.; Rivera, B.; Farquhar, D.; Price, R. E.; Ravoori, M.; Kundra, V.; Freedman, R. S.; Klostergaard, J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9, 479-486.
63. Rosato, A.; Banzato, A.; De Luca, G.; Renier, D.; Bettella, F.; Pagano, C.; Esposito, G.; Zanovello, P.; Bassi, P. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol. Oncol. 2006, 24, 207-215.
64. Coradini, D.; Pellizzaro, C.; Abolafio, G.; Bosco, M.; Scarlata, I.; Cantoni, S.; Stucchi, L.; Zorzet, S.; Turrin, C.; Sava, G.; Perbellini, A.; Daidone, M. G. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest. New Drugs 2004, 22, 207-217.
65. Fraser, J. R.; Dahl, L. B.; Kimpton, W. G.; Cahill, R. N.; Brown, T. J.; Vakakis, N. Elimination and subsequent metabolism of circulating hyaluronic acid in the fetus. J. Dev. Physiol. 1989, 11, 235-242.
66. Sugahara, S.; Okuno, S.; Yano, T.; Hamana, H.; Inoue, K. Characteristics of tissue distribution of various polysaccharides as drug carders: influences of molecular weight and anionic charge on tumor targeting. Biol. Pharm. Bull. 2001, 24, 535-543.
67. Mahteme, H.; Graf, W.; Larsson, B. S.; Gustafson, S. Uptake of hyaluronan in hepatic metastases after blocking of liver endothelial cell receptors. Glycoconjugate J. 1998, 15, 935-939.
68. Weigel, J. A.; Raymond, R. C.; McGary, C.; Singh, A.; Weigel, P. H. A blocking antibody to the hyaluronan receptor for endocytosis (HARE) inhibits hyaluronan clearance by perfused liver. J. Biol. Chem. 2003, 278, 9808-9812.
69. Peer, D.; Margalit, R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004, 6, 343-353.
70. Peer, D.; Margalit, R. Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. J. Cancer 2004, 108, 780-789.
71. Yadav, A. K.; Mishra, P.; Mishra, A. K.; Mishra, P.; Jain, S.; Agrawal, G. P. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine 2007, 3, 246-257.
72. Lee, H.; Mok, H.; Lee, S.; Oh, Y. K.; Park, T. G. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J. Controlled Release 2007, 119, 245-252.
73. Kumar, A.; Sahoo, B.; Montpetit, A.; Behera, S.; Lockey, R. F.; Mohapatra, S. S. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nano-medicine 2007, 3, 132-137.
74. Yun, Y. H.; Goetz, D. J.; Yellen, P.; Chen, W. Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials 2004, 25, 147-157.
75. Yerushalmi, N.; Arad, A.; Margalit, R. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch. Biochem. Biophys. 1994, 313, 267-273.
76. Hyung, W.; Ko, H.; Park, J.; Lim, E.; Park, S. B.; Park, Y. J.; Yoon, H. G.; Suh, J. S.; Haam, S.; Huh, Y. M. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnol. Bioeng. 2008, 99, 442-454.
77. Ziebell, M. R.; Zhao, Z. G.; Luo, B.; Luo, Y.; Turley, E. A.; Prestwich, G. D. Peptides that mimic glycosaminoglycans: high-affinity ligands for a hyaluronan binding domain. Chem. Biol. 2001, 8, 1081-1094.
78. Rezler, E. M.; Khan, D. R.; Lauer-Fields, J.; Cudic, M.; Baronas-Lowell, D.; Fields, G. B. Targeted drug delivery utilizing protein-like molecular architecture. J. Am. Chem. Soc. 2007, 129, 4961-4972.
79. Day, A. J.; Prestwich, G. D. Hyaluronan-binding proteins: tying up the giant. J. Biol. Chem. 2002, 277, 4585-4588.
80. Shuster, S.; Frost, G. I.; Csoka, A. B.; Formby, B.; Stem, R. Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int. J. Cancer 2002, 102, 192-197.
81. Eikenes, L.; Tari, M.; Tufto, I.; Bruland, O. S.; de Lange Davies, C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer 2005, 93, 81-88.
82. Bartolazzi, A.; Peach, R.; Aruffo, A.; Stamenkovic, I. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med. 1994, 180, 53-66.
83. Yu, Q.; Toole, B. P.; Stamenkovic, I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med. 1997, 186, 1985-1996.
84. Peterson, R. M.; Yu, Q.; Stamenkovic, I.; Toole, B. P. Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am. J. Pathol. 2000, 156, 2159-2167.
85. Ahrens, T.; Sleeman, J. P.; Schempp, C. M.; Howells, N.; Hofmann, M.; Ponta, H.; Herrlich, P.; Simon, J. C. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 2001, 20, 3399-3408.
86. Subramaniam, V.; Gardner, H.; Jothy, S. Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp. Mol. Pathol. 2007, 83, 341-346.
87. Mohapatra, S.; Yang, X.; Wright, J. A.; Turley, E. A.; Greenberg, A. H. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J. Exp. Med. 1996, 183, 1663-1668.
88. Akiyama, Y.; Jung, S.; Salhia, B.; Lee, S.; Hubbard, S.; Taylor, M.; Mainprize, T.; Akaishi, K.; van Furth, W.; Rutka, J. T. Hyaluronate receptors mediating glioma cell migration and proliferation. J. Neurooncol. 2001, 53, 115-127.
89. Xu, X. M.; Chen, Y.; Chen, J.; Yang, S.; Gao, F.; Underhill, C. B.; Creswell, K.; Zhang, L. A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res. 2003, 63, 5685-5690.